The economics of biosimilars.

@article{Blackstone2013TheEO,
  title={The economics of biosimilars.},
  author={Erwin A. Blackstone and P Fuhr Joseph},
  journal={American health & drug benefits},
  year={2013},
  volume={6 8},
  pages={469-78}
}
BACKGROUND The high cost of pharmaceuticals, especially biologics, has become an important issue in the battle to control healthcare costs. The Hatch-Waxman Act encourages generic competition but still provides incentives for pioneers to develop new drugs. The Biologics Price Competition and Innovation Act is intended to do the same for biologics and biosimilars. OBJECTIVE To examine information related to biosimilars to determine their potential impact on competition in the biologic market… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
28 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Analysis: Roche stays a step ahead of copycat drugmakers

  • C. Copley
  • Reuters. March 25,
  • 2013

Bio-dynamism: insights into the biosimilars market: an overall perspective

  • Grant Thornton India
  • www.grantthornton.in/assets/BioAsia_2013.pdf…
  • 2013

Biosimilars face big delays as blockbuster knockoffs hit a roadblock

  • J. Carroll
  • FierceBiotech. February
  • 2013

Biosimilars lure major drugmakers into the generics biz

  • M Kitamura, D. Wainer
  • BloombergBusinessweek. March
  • 2013

Biosimilars: is the market getting too much attention? BioPharmaReporter.com

  • Z. Brennan
  • March 6,
  • 2013

Biotech drugs still won’t copy

  • C Weaver, J Whalen, JD. Rockoff
  • Wall Street Journal. February
  • 2013

Celltrion slides to third in race for Roche rituximab biosimilar with planned 2H13 phase III trial start

  • K Barnes, K Kim, SY. Park
  • Financial Times. April
  • 2013

Conquering the complexities of biologics to get to biosimilars

  • E. Palmer
  • Fierce PharmaManufacturing. March
  • 2013

Data submitted before 2010 shouldn’t be used to approve biosimilars, group says

  • A. Gaffney
  • Regulatory Focus. April
  • 2013

First copy of J&J’s $6 billion Remicade wins EMA backing

  • M Kitamura, S. Kang
  • Bloomberg. July
  • 2013

Similar Papers

Loading similar papers…